Escitalopram
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Social Anxiety Disorder
Conditions
Social Anxiety Disorder
Trial Timeline
Mar 1, 2009 → Mar 1, 2010
NCT ID
NCT00902226About Escitalopram
Escitalopram is a approved stage product being developed by Lundbeck for Social Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00902226. Target conditions include Social Anxiety Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00902564 | Approved | Completed |
| NCT00902226 | Approved | Completed |
| NCT00935246 | Pre-clinical | UNKNOWN |
| NCT00442481 | Approved | UNKNOWN |
| NCT00708240 | Approved | UNKNOWN |
| NCT00397059 | Approved | Completed |
| NCT00456937 | Approved | Completed |
| NCT00464191 | Approved | Terminated |
| NCT00243477 | Approved | Completed |
| NCT00232700 | Pre-clinical | Completed |
| NCT00162968 | Approved | Completed |
| NCT00229333 | Approved | UNKNOWN |
| NCT00140257 | Approved | UNKNOWN |
| NCT00148447 | Phase 3 | Completed |
Competing Products
20 competing products in Social Anxiety Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY686017 + paroxetine + placebo | Eli Lilly | Phase 2 | 52 |
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Cariprazine + Placebo | AbbVie | Approved | 85 |
| Quetiapine | AstraZeneca | Approved | 85 |
| quetiapine | AstraZeneca | Phase 3 | 77 |
| quetiapine | AstraZeneca | Phase 2/3 | 65 |
| Seroquel + Sugar Pill | AstraZeneca | Phase 3 | 77 |
| quetiapine | AstraZeneca | Approved | 85 |
| Pristiq + Placebo | Pfizer | Approved | 84 |
| Venlafaxine ER | Pfizer | Phase 3 | 76 |
| Ziprasidone + Sertraline | Pfizer | Phase 2 | 51 |
| Sertraline + Placebo | Pfizer | Approved | 84 |
| Nefazodone | Bristol Myers Squibb | Approved | 84 |
| Cipralex + Placebo | Lundbeck | Phase 2 | 49 |
| BHV-0223 + Placebo | Biohaven | Phase 2/3 | 60 |
| VQW-765 + Placebo | Vanda Pharmaceuticals | Phase 3 | 69 |
| PH94B | Vistagen Therapeutics | Phase 3 | 69 |
| Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray | Vistagen Therapeutics | Phase 2 | 44 |
| PH94B Nasal Spray + Placebo Nasal Spray | Vistagen Therapeutics | Phase 3 | 69 |